Paxlovid is “a tremendous tool that’s completely underutilized” One of the best tools for preventing severe complications from COVID infection is the prescription antiviral drug Paxlovid. But not nearly as many people who could benefit from it are being prescribed it, says Amesh Adalja, MD, FIDSA, a senior scholar at the Johns […]
Patients with mild to moderate COVID-19 who were treated for 5 days with VV116, an investigational oral antiviral drug that is active against SARS-CoV-2, recovered as quickly from infection as did those treated with nirmatrelvir-ritonavir (Paxlovid), according to the results of a randomized noninferiority trial published in the New England […]
The antiviral drug Paxlovid appears to reduce the risk of dying from COVID-19 by 79% and decrease hospitalizations by 73% in at-risk patients who are ages 65 and older, according to a new study published in The New England Journal of Medicine. The pill, which is a combination of the drugs nirmatrelvir and ritonavir, […]
Expiration dates have been extended from 9 months after manufacture to 12 months for 4 lots of the COVID-19 antiviral therapy Paxlovid, which consists of copackaged nirmatrelvir tablets and ritonavir tablets. The lot numbers and original expiration dates are listed on the FDA website. The nirmatrelvir-ritonavir lots were manufactured before the FDA […]
In a Think Global Health article, IHME staff examine the barriers to acquiring the antiviral Paxlovid, which can greatly reduce the chance of COVID-19 hospitalizations and deaths. Low- and middle-income nations must contend with licensing dilemmas, lack of supplies, and high costs to gain access to Paxlovid. “This would be similar to the […]
México recibió los primeros 180 mil tratamientos de Paxlovid, un medicamento para tratar el COVID-19. La Secretaría de Salud informó el miércoles que estos medicamentos serán suministrados sin costo a personas con salud vulnerable. “El Paxlovid impide que el SARS-CoV-2 pueda replicarse, por lo que es recomendado para personas con cuadro leve o moderado de COVID-19 con alto […]
David Ho, MD, managed to avoid contracting COVID-19 for more than 2 years. But SARS-CoV-2 finally got the best of the pioneering HIV researcher on an April trip to Paris for, of all things, a 2-day COVID-19 conference. The irony is not lost on Ho, director of the Aaron Diamond […]
